Northern Trust Corp Raises Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Northern Trust Corp increased its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 21.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 245,523 shares of the company's stock after purchasing an additional 42,923 shares during the quarter. Northern Trust Corp owned approximately 0.83% of Dianthus Therapeutics worth $5,352,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. R Squared Ltd acquired a new position in Dianthus Therapeutics during the fourth quarter worth $26,000. KLP Kapitalforvaltning AS bought a new stake in Dianthus Therapeutics during the fourth quarter worth $33,000. KBC Group NV bought a new stake in Dianthus Therapeutics during the fourth quarter worth $35,000. AlphaQuest LLC raised its position in Dianthus Therapeutics by 273.1% during the fourth quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock worth $91,000 after acquiring an additional 3,072 shares in the last quarter. Finally, Intech Investment Management LLC bought a new stake in Dianthus Therapeutics during the fourth quarter worth $201,000. Institutional investors and hedge funds own 47.53% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Guggenheim reaffirmed a "buy" rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Wedbush reaffirmed an "outperform" rating and set a $36.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Robert W. Baird dropped their price target on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 13th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $53.00.

Dianthus Therapeutics Stock Up 0.3%

Shares of DNTH traded up $0.06 during trading hours on Friday, hitting $18.42. The company had a trading volume of 234,992 shares, compared to its average volume of 273,124. The firm has a market cap of $592.39 million, a price-to-earnings ratio of -7.37 and a beta of 1.48. The business has a fifty day moving average of $19.13 and a 200-day moving average of $21.83. Dianthus Therapeutics, Inc. has a 12 month low of $13.37 and a 12 month high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.04. The company had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.81 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, equities analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.